HIV News and Research

RSS

Researchers develop personalized tool to predict likelihood of prostate cancer overdiagnosis

Studies have found that prostate cancer is overdiagnosed in up to 42 percent of cases, prompting men to receive unnecessary treatment that can cause devastating side effects, including impotence and incontinence.

9 Jan 2014

Biogen Idec, Sangamo BioSciences partner to develop therapeutics for hemoglobinopathies

Biogen Idec and Sangamo BioSciences, Inc. announced today an exclusive worldwide collaboration and license agreement focused on the development of therapeutics for hemoglobinopathies, inherited conditions that result from the abnormal structure or underproduction of hemoglobin.

9 Jan 2014

Mylan announces launch of Mycophenolic Acid Delayed-release Tablets

Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Mycophenolic Acid Delayed-release Tablets, 180 mg and 360 mg. This product is the generic version of Novartis' Myfortic Delayed-release Tablets.

9 Jan 2014

Zyomyx's MyT4 point-of-care CD4 diagnostic test receives CE mark approval

Mylan, Inc. today announced that Zyomyx's MyT4 point-of-care CD4 diagnostic test has received the CE Certificate of Conformity in the European Union, an important step toward launching this innovative test and expanding access to affordable, accessible and reliable diagnostics for people living with HIV globally.

9 Jan 2014

Viewpoints: Health law debate on contraceptive coverage; Cuccinelli: No investigators for Medicaid fraud; 50 years after the famed report on smoking

The Little Sisters of the Poor, an organization of Roman Catholic nuns that runs nursing homes around the country, is testing the contraceptive coverage mandate of the Affordable Care Act. Last week, we're sorry to say, the nuns won a temporary reprieve from Supreme Court Justice Sonia Sotomayor. Under the law, most employers are required to provide their employees with health insurance that covers birth control. But the Obama administration agreed to a compromise for nonprofit religious groups that object to contraception, exempting them from paying for such coverage. Instead, insurers agreed to absorb the cost. All the religious organization has to do is fill out a simple form attesting to its situation. Unfortunately, even that was too much for the Little Sisters of the Poor (1/7).

9 Jan 2014

Study identifies risk factors linked with non-fatal overdose among HIV-infected Russians

Researchers from Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) have identified that injection frequency and taking anti-retroviral therapy for HIV are risk factors for nonfatal drug overdoses among Russians who are HIV positive and inject drugs.

9 Jan 2014

Merck announces FDA approval of ISENTRESS for oral suspension

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration recently approved ISENTRESS for oral suspension, a new pediatric formulation of Merck's integrase inhibitor. With this approval, ISENTRESS is now indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in patients four weeks of age and older.

9 Jan 2014

Hebrew University research could lead to efficient and fast-acting antidepressant drugs

The World health Organization calls depression "the leading cause of disability worldwide," causing more years of disability than cancer, HIV/AIDS, and cardiovascular and respiratory diseases combined.

8 Jan 2014

C. parvum and cryptosporidiosis: an interview with Dr. Momar Ndao, McGill University

Cryptosporidium parvum is one of the most common enteropathogens to affect humans in the world. The protozoan parasite causes a gut infection referred to as cryptosporidiosis.

8 Jan 2014

Research findings could affect how drugs are developed to treat autoimmune diseases

Researchers at Johns Hopkins have zoomed in on what is going on at the molecular level when the body recognizes and defends against an attack of pathogens, and the findings, they say, could influence how drugs are developed to treat autoimmune diseases.

8 Jan 2014

Researchers explore molecular level changes when body recognizes, defends against pathogens

8 Jan 2014

AHF opens new Men's Wellness Center in Brooklyn in partnership with GMAD

AIDS Healthcare Foundation will open its newest Men's Wellness Center in Brooklyn on Wednesday in partnership with local nonprofit Gay Men of African Descent.

8 Jan 2014

CytoDyn receives FDA approval to start Phase 2b study of PRO 140 for treatment of HIV-1

CytoDyn Inc., a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today the Company has received approval from the United States Food and Drug Administration (FDA) to commence patient screening of a Phase 2b study of PRO 140, a monoclonal CCR5 antibody, for the treatment of patients with Human Immunodeficiency Virus Type 1.

8 Jan 2014

Mylan launches Tolterodine Tartrate ER Capsules, 2 mg and 4 mg

Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Tolterodine Tartrate Extended-release Capsules, 2 mg and 4 mg. Tolterodine Tartrate ER Capsules are the generic version of Pfizer's Detrol LA, and are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product.

7 Jan 2014

Study: Long-term weight loss maintenance possible if individuals adhere to key health behaviors

Researchers from The Miriam Hospital have published one of the first studies of its kind to follow weight loss maintenance for individuals over a 10-year period. The results show that long-term weight loss maintenance is possible if individuals adhere to key health behaviors. The study is published in the January 2014 issue of the American Journal of Preventive Medicine.

7 Jan 2014

Population Council gets USAID cooperative agreement to develop non-ARV microbicides that block HIV, STI

The Population Council today announced it was awarded a cooperative agreement from the US Agency for International Development's (USAID) Office of HIV and AIDS: "Non-ARV Based Combination Microbicide that Blocks HIV and Other STIs."

6 Jan 2014

The fight against HIV/AIDS: an interview with Dr. Mit Philips, HIV/AIDS Policy Analyst, Médecins Sans Frontières (MSF)

People mainly speak about the progress in HIV/AIDS. We at MSF know and are very conscious of the fact that there has been enormous progress, but the progress is very uneven.

6 Jan 2014

Special publication details breakthrough research on causes of vascular disease

The world's leading voices in the fight against Pulmonary Hypertension have compiled a special publication detailing the breakthrough research into the causes of this debilitating vascular disease.

6 Jan 2014

Astellas, ClearPath announce strategic partnership to develop vaccine for infectious diseases

Astellas Pharma Inc. (Astellas) and ClearPath Development Company (ClearPath) announced today a strategic partnership to form a portfolio of development companies focused on vaccines targeting infectious diseases.

6 Jan 2014

Surgeons develop iPad app to capture trauma patient data in low medical resource environment

Electronic health records have become standard practice throughout hospitals in North America, but in countries with fewer resources many front-line clinicians are still collecting data on paper, if they are collecting it at all. But now, surgeons from Vancouver, British Columbia, have developed a way for their peers at a Level I trauma center in South Africa to accurately collect and analyze trauma care data via an iPad app. The study is published in the January issue of the Journal of the American College of Surgeons.

2 Jan 2014

HIV News and Research

Researchers develop personalized tool to predict likelihood of prostate cancer overdiagnosis

Biogen Idec, Sangamo BioSciences partner to develop therapeutics for hemoglobinopathies

Mylan announces launch of Mycophenolic Acid Delayed-release Tablets

Zyomyx's MyT4 point-of-care CD4 diagnostic test receives CE mark approval

Viewpoints: Health law debate on contraceptive coverage; Cuccinelli: No investigators for Medicaid fraud; 50 years after the famed report on smoking

Study identifies risk factors linked with non-fatal overdose among HIV-infected Russians

Merck announces FDA approval of ISENTRESS for oral suspension

Hebrew University research could lead to efficient and fast-acting antidepressant drugs

C. parvum and cryptosporidiosis: an interview with Dr. Momar Ndao, McGill University

Research findings could affect how drugs are developed to treat autoimmune diseases

Researchers explore molecular level changes when body recognizes, defends against pathogens

AHF opens new Men's Wellness Center in Brooklyn in partnership with GMAD

CytoDyn receives FDA approval to start Phase 2b study of PRO 140 for treatment of HIV-1

Mylan launches Tolterodine Tartrate ER Capsules, 2 mg and 4 mg

Study: Long-term weight loss maintenance possible if individuals adhere to key health behaviors

Population Council gets USAID cooperative agreement to develop non-ARV microbicides that block HIV, STI

The fight against HIV/AIDS: an interview with Dr. Mit Philips, HIV/AIDS Policy Analyst, Médecins Sans Frontières (MSF)

Special publication details breakthrough research on causes of vascular disease

Astellas, ClearPath announce strategic partnership to develop vaccine for infectious diseases

Surgeons develop iPad app to capture trauma patient data in low medical resource environment

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Exploring the G:Box and for high-quality imaging

Latest News